

Independent Auditor's Review report on quarterly unaudited financial results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Review report to
The Board of Directors
GUJARAT THEMIS BIOSYN LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended June 30, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


The Financial results includes the figures for the 3 months ended 31st March, 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and



other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GMJ & Co
Chartered Accountants
FRN: 103429W



CA Sanjeev Maheshwari
Partner
M. No.: 038755
UDIN: 210387 55AAAA EC9044



Place : Mumbai
Date : August 12, 2021

GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter ended June 30, 2021

(INR in Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
I	Income from operations	3,244.05	2,329.84	1,566.30	9,056.27
II	Other Income	113.29	79.54	85.93	326.66
III	Total Income (I+II)	3,357.35	2,409.38	1,652.24	9,382.93
IV	Expenditure				
	(a) Cost of raw material consumed	587.04	82.45	474.48	1,575.29
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-Progress and Stock in Trade	33.03	841.81	(456.18)	(38.11)
	(d) Employee benefits expense	168.35	174.08	167.82	711.27
	(e) Finance Cost	19.56	29.26	23.36	98.14
	(f) Depreciation and Amortisation expenses	54.15	67.07	33.93	173.25
	(g) Other Expenses			-	
	i) Stores and spares	93.35	176.47	94.66	563.57
	ii) Power	386.74	113.44	362.07	1,260.15
	iii) Fuel	146.54	15.25	99.66	329.44
	iv) Water	24.10	10.34	19.46	67.08
	v) Other expenditure	132.52	85.67	145.20	554.66
	Total Expenses	1,645.39	1,595.85	964.47	5,294.74
V	Profit (Loss) before Exceptional Items and Tax (III-IV)	1,711.96	813.54	687.77	4,088.19
VI	Exceptional items	-	-	-	-
VII	Profit (Loss) before Tax (V-VI)	1,711.96	813.54	687.77	4,088.19
VIII	Tax expenses				
	(a) Current Tax	423.88	227.61	130.00	1,057.61
	(b) Deferred Tax	(4.19)	6.87	0.53	12.62
IX	Net Profit (Loss) after tax (VII-VIII)	1,292.27	579.07	557.24	3,017.97
X	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss				
	(i) remeasurement of defined benefit plans;	(1.04)	-4.25	0.03	(4.15)
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	0.27	1.10	(0.01)	1.08
	(b) Items that will be reclassified to Profit or Loss				
	(i) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
XI	Total Comprehensive Income for the period (IX+X)	1,291.50	575.91	557.27	3,014.89
XII	Paid-up equity share capital	726.40	726.40	726.40	726.44
XIII	Other Equity	-	-	-	6,268.28
XIV	Earnings Per Share (Basic and Diluted)	8.89	3.99	3.84	20.77




Notes:

- 1 The financial results for the quarter and year ended June 30, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 12, 2021 .In compliance with Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, a limited review of financial results for the quarter ended 30 June 2021 has been carried out by the Statutory Auditors.
- 2 Operating segments are reported in manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") of the Company . The CODM, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (CEO) of the Company. The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 The beginning of the first quarter of Financial Year 2021-22 saw the rise of the second wave of Covid 19 resulting in the same being more contagious thereby affecting a huge number of the India's population and as regards the Company, quite a few members of its Top management. The rise of the second wave led to various state governments imposing several restrictions to combat the virus which impacted economic activities in the country. While the Company was affected generally to some extent, there was no material impact on its manufacturing operations.
- 5 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been notified in the Gazette of India. However, the date from which it will be implemented has reportedly not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 6 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

Place: Mumbai
Date : August 12, 2021



For GUJARAT THEMIS BIOSYN LIMITED


Dr. DINESH PATEL

Chairman

DIN : 00033273